• What Multiplexed CRISPR Evidence Supports

  2026-10-12

  A source-grounded overview of what multiplexed CRISPR can achieve in principle, what the evidence actually establishes, and why a three-guide ANGPTL3 product listing cannot by itself demonstrate editing performance, safety, or therapeutic relevance.

• Nutlin-3a, p53, and the GBM Evidence Gap

  2026-10-12

  The supplied evidence links miR-18a and ALOXE3 to ferroptosis resistance and migration in glioblastoma, while Nutlin-3a is described by its supplier as an MDM2 inhibitor that activates p53 signaling. No direct published comparison in the supplied record establishes that Nutlin-3a reproduces, reverses, or modifies the ALOXE3-associated phenotype.

• 11β-HSD1 Inhibition and Liver Fibrosis

  2026-10-11

  A 2025 mouse study examined whether a novel 11β-HSD1 inhibitor could reduce toxin-associated liver fibrosis and explored Notch signaling and natural-killer-cell responses as possible mediators. The reported findings support an antifibrotic association in that model, but they do not establish clinical efficacy, applicability to human MASLD/MASH, or equivalence to Obeticholic Acid, an FXR-directed bile acid homeostasis modulator.

• DeferoxamineB and the Logic of Cell-Death Evidence

  2026-10-10

  DeferoxamineB is more than an iron chelator: it can help researchers interpret whether metabolic stress is genuinely iron-dependent. This article examines its evidentiary value alongside ferroptosis, cuproptosis, antioxidant regulation, and the metabolic intervention strategy reported by Zhang et al.

• IWP-2: Five Questions About Wnt Evidence

  2026-10-09

  IWP-2 is described as a Porcupine-targeting Wnt production inhibitor, but the strength of evidence depends on separating supplier-reported findings from independently published research. This overview explains its proposed mechanism, how to interpret potency and cancer-model results, and why the supplied schizophrenia study does not validate IWP-2.

• Prevotella copri, IPyA, and Breast Cancer Progression

  2026-10-09

  The reference study links enrichment of Prevotella copri with breast cancer progression through depletion of host indole-3-pyruvic acid and downstream disruption of the UHRF1–AMPK regulatory axis. Its combination of human microbiome observations, mouse models, metabolite analysis, and molecular readouts supports a microbiota–metabolite–epigenetic mechanism, while important questions about human causality and clinical applicability remain.

• SQOR, Hypoxia and qRT-PCR Evidence in PDAC

  2026-10-08

  A source-grounded overview of how the 2025 SQOR study connects hypoxia, ferroptosis resistance and pancreatic ductal adenocarcinoma, with careful consideration of reverse-transcription chemistry, qRT-PCR interpretation, evidence strength and applicability limits.

• Geneticin, G-418 Sulfate: From Selection to Translation

  2026-10-08

  Geneticin, G-418 Sulfate is best understood not only as a selection antibiotic but also as a variable that can shape interpretation of translational and ferroptosis research. This thought-leadership perspective connects its protein-synthesis effects with the METTL16-SENP3-LTF axis in hepatocellular carcinoma while defining evidence boundaries, translational opportunities, and responsible study design.

• Multiplexed CRISPR–Cas: Genome Engineering Review

  2026-10-07

  This 2025 review explains how multiplexed CRISPR–Cas systems extend genome engineering beyond single-locus editing to coordinated deletions, structural variants, multi-gene perturbation, epigenetic regulation, and selective cellular damage. Its main implication is that multiplexing broadens experimental scope, while simultaneous DNA breaks also increase the importance of interpreting genotoxicity, editing heterogeneity, and context-specific outcomes.

• Geneticin: From Selection Marker to Cell-State Biology

  2026-10-07

  Geneticin and G418 Sulfate are more than selection reagents: they connect translational stress, engineered-cell enrichment, and context-dependent antiviral observations. This article separates established mechanisms from interpretation, using an EBV–nasopharyngeal carcinoma study to define evidence boundaries.

• Panobinostat Targets MLL-Rearranged Leukemia

  2026-10-06

  A 2018 Leukemia study found that panobinostat produced strong anti-leukaemic effects in MLL-rearranged acute lymphoblastic leukaemia xenograft models and linked this activity to suppression of the RNF20/RNF40/WAC-H2B ubiquitination axis. The work connects HDAC inhibition with a leukemia-maintaining chromatin pathway, while also showing why cell-death measurements should be interpreted alongside molecular and in vivo evidence.

• Macrophages Link Intermittent Hypoxia to Pain

  2026-10-06

  Chivers and colleagues identify peripheral macrophages as a key contributor to nociceptor priming in mice exposed to chronic intermittent hypoxia, a model of recurrent oxygen loss associated with obstructive sleep apnea. By combining behavioral, neurobiological, and immune readouts with macrophage depletion, the study moves beyond correlation toward evidence that macrophage signaling is required for the observed persistent pain phenotype. The findings support further investigation of hypoxia correction and immune mechanisms, while remaining preclinical and model-dependent.

• Sunitinib: RTK Biology and Evidence Boundaries

  2026-10-05

  Sunitinib is a multi-targeted receptor tyrosine kinase inhibitor that suppresses signaling through VEGFR, PDGFR, KIT, and RET. Research in ATRX-deficient high-grade glioma cells supports a biomarker-focused hypothesis for RTK inhibition, but the findings do not establish clinical efficacy in glioma.

• Drug-Sensitized Yeast for mTOR Inhibitor Discovery

  2026-10-05

  A 2025 GeroScience study developed a genetically drug-sensitized yeast platform that detected TOR pathway inhibition far more sensitively than a wild-type background. The system identified known and candidate TOR inhibitors while finding no evidence that canagliflozin inhibited TOR in this model, clarifying the boundary between SGLT2-focused glucose metabolism research and mTOR drug discovery.

• ABT-737 and BAX/BAK Apoptosis: Five Questions

  2026-10-04

  This source-grounded overview explains how ABT-737 is positioned as a BCL-2 protein inhibitor, how the 2024 BAX/BAK imaging study informs apoptosis biology, and where the evidence does—and does not—support conclusions about cancer research.

8052 records 1/537 page Next 12345 下5页 Last page